Literature DB >> 8683757

Comparative urodynamic findings after primary valve ablation, vesicostomy or proximal diversion.

Y H Kim1, M Horowitz, A Combs, V W Nitti, D Libretti, K I Glassberg.   

Abstract

PURPOSE: There is little known about the effect of urinary diversion on the bladder of children with posterior urethral valves. There is a fear that diversion may result in contracted noncompliant bladders. We wished to compare urodynamic parameters in patients who underwent primary ablation of posterior urethral valves and in those who underwent diversion in the form of vesicostomy or pyelostomy.
MATERIALS AND METHODS: Urodynamics were done in 32 boys with a history of posterior urethral valves divided into 3 groups based on initial treatment: 1) transurethral valve ablation; 2) cutaneous vesicostomy, subsequent closure and valve ablation, and 3) proximal cutaneous pyelostomy, subsequent reconstitution and valve ablation.
RESULTS: Patients who underwent initial diversion with vesicostomy or pyelostomy had bladders with larger functional capacity, better compliance and less instability. Chronic renal failure developed in 25% of the patients who underwent primary valve ablation and 33% of those who underwent diversion. Average period of diversion in vesicostomy and pyelostomy patients was 25 months.
CONCLUSIONS: Based on our findings temporary diversion does not seem to damage bladders. On the contrary, placing a damaged bladder at rest may help to improve bladder function. Bladder function following reconstitution correlated poorly with ultimate outcome and progression to renal failure. While we do not recommend temporary diversion as the treatment of choice for patients with posterior urethral valves, we believe that when chosen as treatment, it can be safely performed with little risk of further damage to the bladder.

Entities:  

Mesh:

Year:  1996        PMID: 8683757     DOI: 10.1097/00005392-199608001-00028

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

Review 1.  Initial and long-term management of posterior urethral valves.

Authors:  P López Pereira; M J Martinez Urrutia; E Jaureguizar
Journal:  World J Urol       Date:  2004-11-19       Impact factor: 4.226

2.  Efficacy of bladder neck incision on urodynamic abnormalities in patients with posterior urethral valves.

Authors:  Yogesh K Sarin; Shalini Sinha
Journal:  Pediatr Surg Int       Date:  2013-04       Impact factor: 1.827

Review 3.  All grown up: A transitional care perspective on the patient with posterior urethral valves.

Authors:  Melise A Keays; Kristen Mcalpine; Blayne Welk
Journal:  Can Urol Assoc J       Date:  2018-04       Impact factor: 1.862

Review 4.  Effects of posterior urethral valves on long-term bladder and sexual function.

Authors:  Seppo Taskinen; Jukka Heikkilä; Risto Rintala
Journal:  Nat Rev Urol       Date:  2012-11-13       Impact factor: 14.432

Review 5.  [Urethral valves. Fate of the bladder and upper urinary tract].

Authors:  M C Carr; H M Snyder
Journal:  Urologe A       Date:  2004-04       Impact factor: 0.639

Review 6.  A systematic review on renal and bladder dysfunction after endoscopic treatment of infravesical obstruction in boys.

Authors:  Pauline M L Hennus; Geert J M G van der Heijden; J L H Ruud Bosch; Tom P V M de Jong; Laetitia M O de Kort
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

7.  Bladder function in children with posterior urethral valves: impact of antenatal versus postnatal diagnosis.

Authors:  Osama M Sarhan; Bassem Wadie; Fouad Al-Kawai; Mohamed Dawaba
Journal:  Int Braz J Urol       Date:  2022 Jan-Feb       Impact factor: 1.541

8.  A review of urodynamic evaluation in children and its role in the management of boys with posterior urethral valves.

Authors:  Divyesh Y Desai
Journal:  Indian J Urol       Date:  2007-10

Review 9.  The valve bladder: etiology and outcome.

Authors:  Enrique Jaureguizar; Pedro López-Pereira; M José Martinez-Urrutia
Journal:  Curr Urol Rep       Date:  2002-04       Impact factor: 2.862

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.